2015•Clinical Lymphoma Myeloma & LeukemiaRequires access

Bortezomib- and carfilzomib-resistant multiple myeloma cells generated in vitro match the molecular hallmarks of bortezomib-resistant primary myeloma cells, but differ in their sensitivity to bortezomib, carfilzomib and novel proteasome inhibiting drugs

L. Besse, A. Besse, Bogdan I. Florea, G.P. Soriano, Jürgen Bader, Herman S. Overkleeft, Marianne Kraus, Christoph Driessen

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Carfilzomib, Bortezomib, Ixazomib, Proteasome inhibitor, Multiple myeloma, Proteasome, Cancer research, In vitro

Back to paper search Browse research topics Original source

Bortezomib- and carfilzomib-resistant multiple myeloma cells generated in vitro match the molecular hallmarks of bortezomib-resistant primary myeloma cells, but differ in their sensitivity to bortezomib, carfilzomib and novel proteasome inhibiting drugs — Research Paper | ScholarLens